BRAINSWAY LTD/S (NASDAQ:BWAY) has earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $16.75.
Separately, Zacks Investment Research raised shares of BRAINSWAY LTD/S from a “sell” rating to a “hold” rating in a report on Monday, October 21st.
BWAY traded up $0.09 during mid-day trading on Wednesday, reaching $8.65. 3,100 shares of the stock were exchanged, compared to its average volume of 10,884. The business has a 50 day moving average of $9.43. BRAINSWAY LTD/S has a 1 year low of $8.00 and a 1 year high of $12.39.
BRAINSWAY LTD/S (NASDAQ:BWAY) last issued its quarterly earnings results on Monday, August 26th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.06). The company had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.30 million. As a group, sell-side analysts forecast that BRAINSWAY LTD/S will post -0.52 EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Victory Capital Management Inc. purchased a new position in shares of BRAINSWAY LTD/S in the 2nd quarter worth about $157,000. Noked Capital LTD purchased a new position in shares of BRAINSWAY LTD/S in the 2nd quarter worth about $572,000. ARK Investment Management LLC purchased a new position in shares of BRAINSWAY LTD/S in the 2nd quarter worth about $863,000. Finally, Delek Group Ltd. purchased a new position in shares of BRAINSWAY LTD/S in the 2nd quarter worth about $3,176,000. 10.84% of the stock is currently owned by institutional investors.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Story: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.